Q4 EPS Forecast for Denali Therapeutics Lowered by Analyst

Key Points

• Leerink Partnrs has revised its Q4 2025 earnings per share estimate for Denali Therapeutics to ($0.82), reflecting a slight decrease from the previous estimate of ($0.80).
• The company reported ($0.72) EPS in its last quarterly earnings, surpassing analysts' expectations but showing a decline from the prior year's EPS of ($0.59).
• Despite recent price target reductions from various analysts, the stock maintains a consensus rating of "Buy" and an average price target of $33.85.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at Leerink Partnrs lowered their Q4 2025 EPS estimates for Denali Therapeutics in a report released on Tuesday, August 12th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.80). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Denali Therapeutics' FY2026 earnings at ($2.25) EPS, FY2027 earnings at ($2.40) EPS, FY2028 earnings at $0.55 EPS and FY2029 earnings at $0.70 EPS.

Several other equities analysts also recently weighed in on the stock. Bank of America reduced their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Robert W. Baird reduced their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. TD Cowen upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. HC Wainwright reduced their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Wedbush reduced their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $33.62.

Denali Therapeutics Stock Performance

DNLI stock traded up $0.05 during mid-day trading on Friday, hitting $14.87. The company had a trading volume of 50,760 shares, compared to its average volume of 1,404,269. The firm has a market cap of $2.17 billion, a PE ratio of -5.32 and a beta of 1.36. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. The stock's fifty day moving average price is $14.30 and its two-hundred day moving average price is $15.19. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same quarter in the prior year, the business posted ($0.59) earnings per share.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, insider Carole Ho sold 2,937 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider directly owned 217,391 shares in the company, valued at $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 2,937 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the sale, the insider owned 242,346 shares of the company's stock, valued at approximately $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 501,962 shares of company stock worth $7,520,799 over the last three months. 12.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Denali Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company's stock worth $79,000 after acquiring an additional 753 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Denali Therapeutics by 7.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company's stock worth $189,000 after acquiring an additional 930 shares during the last quarter. Knights of Columbus Asset Advisors LLC lifted its holdings in shares of Denali Therapeutics by 2.7% in the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock worth $548,000 after acquiring an additional 1,058 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 12.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company's stock worth $190,000 after acquiring an additional 1,543 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.